期刊
EMBO MOLECULAR MEDICINE
卷 7, 期 2, 页码 127-139出版社
WILEY
DOI: 10.15252/emmm.201404137
关键词
Dautophagy; multidrug-resistant; myo-inositol; tuberculosis
资金
- Wellcome Trust
- NIHR Biomedical Research Centre at Addenbrooke's Hospital
- BBSRC
- Papworth Hospital NHS Trust
- BBSRC [BBS/E/B/000C0415] Funding Source: UKRI
- MRC [G0701932, G108/595, MR/M004864/1] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BBS/E/B/000C0415] Funding Source: researchfish
- Medical Research Council [MR/M004864/1, G0701932, G108/595] Funding Source: researchfish
Mycobacterium tuberculosis (MTB) remains a major challenge to global health made worse by the spread of multidrug resistance. We therefore examined whether stimulating intracellular killing of mycobacteria through pharmacological enhancement of macroautophagy might provide a novel therapeutic strategy. Despite the resistance of MTB to killing by basal autophagy, cell-based screening of FDA-approved drugs revealed two anticonvulsants, carbamazepine and valproic acid, that were able to stimulate autophagic killing of intracellular M. tuberculosis within primary human macrophages at concentrations achievable in humans. Using a zebrafish model, we show that carbamazepine can stimulate autophagy in vivo and enhance clearance of M. marinum, while in mice infected with a highly virulent multidrug-resistant MTB strain, carbamazepine treatment reduced bacterial burden, improved lung pathology and stimulated adaptive immunity. We show that carbamazepine induces antimicrobial autophagy through a novel, evolutionarily conserved, mTOR-independent pathway controlled by cellular depletion of myo-inositol. While strain-specific differences in susceptibility to in vivo carbamazepine treatment may exist, autophagy enhancement by repurposed drugs provides an easily implementable potential therapy for the treatment of multidrug-resistant mycobacterial infection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据